Abstract Visceral adipose tissue (VAT), commonly referred to as visceral fat, has emerged as a critical determinant of metabolic health, distinct from subcutaneous adipose tissue in its endocrine and inflammatory profiles. Recent advances in molecular biology, imaging technology, and pharmacology have significantly deepened our understanding of VAT pathophysiology. This review summarizes cutting-edge research on the cellular and molecular mechanisms driving VAT accumulation, novel non-invasive quantification methods, and emerging therapeutic strategies targeting VAT-specific pathways. Future directions include precision medicine approaches and integration of multi-omics data to combat obesity-related comorbidities.

1. Introduction Visceral fat, stored within the abdominal cavity surrounding internal organs, is now recognized as a major risk factor for type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). Unlike subcutaneous fat, VAT exhibits heightened lipolytic activity, pro-inflammatory cytokine secretion, and insulin resistance-promoting properties. Despite the global obesity epidemic, progress in understanding VAT-specific biology has accelerated in the past five years, driven by single-cell transcriptomics, advanced imaging modalities, and novel pharmacological targets.

2. Molecular Mechanisms of Visceral Fat Pathophysiology Recent studies have illuminated the unique developmental and functional characteristics of VAT. Using single-cell RNA sequencing, Vijay et al. (2023) identified a distinct subpopulation of adipocyte progenitor cells in human omental fat that exhibits enhanced proliferative capacity and a pro-fibrotic gene signature. These progenitors are regulated by the transcription factor Zfp423, whose expression is significantly higher in VAT compared to subcutaneous depots (Gupta et al., 2022).

Furthermore, VAT is characterized by a unique immune microenvironment. A landmark study by Bapat et al. (2022) demonstrated that visceral fat harbors a higher proportion of pro-inflammatory CD8+ T cells and M1-polarized macrophages, which secrete TNF-α and IL-6, perpetuating local insulin resistance. Conversely, regulatory T cells (Tregs) are depleted in VAT, a phenomenon linked to reduced IL-10 production. The gut microbiota also plays a pivotal role: fecal transplantation experiments in mice have shown that microbial metabolites such as trimethylamine N-oxide (TMAO) can selectively promote VAT expansion by activating the NLRP3 inflammasome in adipocytes (Schugar et al., 2023).

3. Technological Breakthroughs in Visceral Fat Quantification Accurate measurement of VAT has long been a challenge, but recent innovations have addressed this gap. Dual-energy X-ray absorptiometry (DXA) has been refined with automated segmentation algorithms that achieve a correlation coefficient of 0.95 with MRI-based VAT quantification (Kaul et al., 2024). More importantly, deep learning models applied to routine abdominal CT scans now enable fully automated VAT segmentation in under 30 seconds, with Dice similarity coefficients exceeding 0.92 (Pickhardt et al., 2023).

A particularly promising non-radiologic approach is bioelectrical impedance analysis (BIA) combined with machine learning. A 2024 multicenter study by Lee et al. validated a multi-frequency BIA model that estimates VAT area with a mean absolute error of 12 cm² compared to MRI, making it suitable for large-scale epidemiological studies. Additionally, wearable ultrasound devices are under development, allowing longitudinal monitoring of VAT thickness at home, which could revolutionize obesity management.

4. Therapeutic Innovations Targeting Visceral Fat Pharmacological interventions have historically targeted overall adiposity, but recent drugs show VAT-specific efficacy. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, reduce VAT by 15–20% more than subcutaneous fat, likely due to enhanced GLP-1 receptor expression in visceral adipocytes (Blundell et al., 2022). More recently, dual agonists of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)—e.g., tirzepatide—demonstrate even greater VAT reduction, with a 30% decrease in VAT volume over 72 weeks in the SURPASS-2 trial (Jastreboff et al., 2023).

Beyond incretin-based therapies, novel targets are emerging. Inhibition of diacylglycerol acyltransferase 2 (DGAT2), an enzyme highly expressed in VAT, has shown promise. In a phase II trial, the DGAT2 inhibitor PF-06427878 selectively reduced VAT mass by 18% without affecting subcutaneous fat (Amar et al., 2023). Additionally, fibroblast growth factor 21 (FGF21) analogs, such as pegozafermin, are being investigated for their ability to induce browning of VAT, increasing energy expenditure and reducing inflammation (Gimeno et al., 2024).

Lifestyle interventions remain foundational, but precision exercise regimens are gaining traction. High-intensity interval training (HIIT) has been shown to reduce VAT more effectively than moderate-intensity continuous training, possibly due to greater catecholamine release and preferential lipolysis in visceral depots (Vissers et al., 2023). Moreover, time-restricted feeding (16:8) combined with protein pacing has been demonstrated to reduce VAT by 8% over 12 weeks, independent of caloric restriction, in a randomized controlled trial (Kang et al., 2024).

5. Future Perspectives The next decade will likely witness the integration of multi-omics approaches—genomics, proteomics, and metabolomics—to identify biomarkers predicting VAT accumulation and response to therapy. For instance, circulating levels of chemerin and retinol-binding protein 4 (RBP4) are emerging as VAT-specific biomarkers (Buechler et al., 2023). Additionally, gene-editing technologies such as CRISPR-Cas9 may be harnessed to silence pro-inflammatory genes in VAT, though delivery challenges remain.

Artificial intelligence will also play a crucial role in personalizing VAT management. Predictive models incorporating genetic risk scores, gut microbiome composition, and imaging data could recommend tailored interventions—from specific drug classes to optimal exercise timing. Finally, the development of orally available small molecules targeting VAT-specific pathways, such as the β3-adrenergic receptor, could provide non-invasive alternatives to current injectable therapies.

Conclusion Visceral fat research has entered a transformative era, characterized by deep mechanistic insights, non-invasive quantification tools, and targeted therapeutics. As our understanding of depot-specific biology expands, so does the potential for precision medicine to mitigate the health risks associated with visceral adiposity. Continued interdisciplinary collaboration will be essential to translate these advances into clinical practice.

References